Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

Renée Eugénie Poupon, Keith Lindor, Albert Parés, Olivier Chazouillères, Raoul Poupon, E. Jenny Heathcote

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.

Original languageEnglish (US)
Pages (from-to)12-16
Number of pages5
JournalJournal of Hepatology
Volume39
Issue number1
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Placebos
Biopsy
Therapeutics
varespladib methyl
Clinical Trials
Liver
Pharmaceutical Preparations

Keywords

  • Histologic features
  • Histologic progression
  • Liver fibrosis
  • Medical treatment
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. / Poupon, Renée Eugénie; Lindor, Keith; Parés, Albert; Chazouillères, Olivier; Poupon, Raoul; Heathcote, E. Jenny.

In: Journal of Hepatology, Vol. 39, No. 1, 01.07.2003, p. 12-16.

Research output: Contribution to journalArticle

Poupon, Renée Eugénie ; Lindor, Keith ; Parés, Albert ; Chazouillères, Olivier ; Poupon, Raoul ; Heathcote, E. Jenny. / Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. In: Journal of Hepatology. 2003 ; Vol. 39, No. 1. pp. 12-16.
@article{2f02113ce2b941a7b698bcadda471bb9,
title = "Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis",
abstract = "Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.",
keywords = "Histologic features, Histologic progression, Liver fibrosis, Medical treatment, Primary biliary cirrhosis",
author = "Poupon, {Ren{\'e}e Eug{\'e}nie} and Keith Lindor and Albert Par{\'e}s and Olivier Chazouill{\`e}res and Raoul Poupon and Heathcote, {E. Jenny}",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0168-8278(03)00192-2",
language = "English (US)",
volume = "39",
pages = "12--16",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

AU - Poupon, Renée Eugénie

AU - Lindor, Keith

AU - Parés, Albert

AU - Chazouillères, Olivier

AU - Poupon, Raoul

AU - Heathcote, E. Jenny

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.

AB - Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.

KW - Histologic features

KW - Histologic progression

KW - Liver fibrosis

KW - Medical treatment

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=0038170271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038170271&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(03)00192-2

DO - 10.1016/S0168-8278(03)00192-2

M3 - Article

C2 - 12821038

AN - SCOPUS:0038170271

VL - 39

SP - 12

EP - 16

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -